Are you a patient with moderate to severe plaque psoriasis?
Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.